<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 113 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page112.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=113">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 113 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 113</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=113"><img src="../thumb/113.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>82 / 2020-04                                                        Musculo-Skeletal Agents - 4.7.1
   dis., oesophag.abnorm.that may delay empty., inabil. to stand/sit   stiffn., joint swell., musc.spasm., arthrit., musc.weakn., jaw necros.,   See prod. lit.for instruct.for prep.reduc.dos. Liq.conc. must be furth.
   upright for at least 30 mins., safety in childr.not est., pregn.& lactat.  ac.ren.fail., fev, flu-like sympts, chills, fatig., asthen., pain, malaise,   dil.in 100 ml NaCl 0,9% or 5% gluc. sol.and admin.as sngl.IV infus.
   Side effects: Headache, uveitis, GI effs.incl. oesophag. eros./ulcerat.  periph.oed., thirst, ac.phase react., non-card.chest pain, thrombo-  in a separ.line over no less than 15 min. Min.of 7 days bef.retreatm.
   follow.by strict., dysphag., oropharyng.ulcerat., gastr./duod.ulc., ab-  phlebit., second.dehydrat.,   Contraindications: Sev.ren.impairm., safety in pregn.& lactat.not
   dom.pain, melaena, rash, erythema, musculoskelet. pain, osteone-  Warnings and special precautions: Caut.with concom. meds.  est., limit.data for use in sev. hepat.insuffic., safety & effic.in paed.
   cros.of jaw, hypersens. reacts.incl.angioed., poss.decr.Ca absorpt. in   poss.impact.ren.funct./meas.ser. creatin. bef.each dos./hydrate the   pts.not est., do not mix.with Ca cont.sols.
   pts.receiv.concom. glucocortic.  elderly & pts. receiv.diuiret.ther.bef.admin.& sngl.dos.not to exceed   Side effects: Bld.dyscras., hypersens./loc.reacts., angioed., psych.
   Special precautions: Correct hypocalcaem.& Vit.D defic.bef.init.  5 mg & infus.time should not be less than 15 mins.to minim.adverse   disords.incl.hallucinat., CNS effs, paraesthes., hypo-/hyperaesthes.,
   ther., dent.exam.& prevent. dentistry for pts.with concomit.risk fact.  ren.reacts., treat.pre-exist.hypocalcaem.with adeq.Ca & Vit.D bef.init.   dizzin., headache, tremor, eye disords.incl.orbit.pain & swell./episcle-
   who should avoid/have indiv.benef/risk assessm.bef. invas.dent.pro-  ther., treat dimin.parathyr.reserve & thyroid or parathyroid surg. & in-  rit., vertigo, bradycard., dyspn., cough, URTI, pleur.effus., bronchosp.,
   ced.as dent.surg.may exacerb.jaw osteonecros., beverages other than   testin.Ca malabsorpt.bef. commenc.ther., adeq.Ca & vit D supplemen-  interstit. pneumonit., sore throat, GI disturbs., dysphag., mucosit., sto-
   plain water, incl.mineral water may reduc.absorpt., supplement. Ca &   tat., vit. D & Ca supplement.in Paget’s dis.treatm.due to characterist.  matit., dry mouth, thirst, liv.enzym. disturbs., monilias., alopec., skin
   Vit.D advis.esp.in pts.receiv. glucocortic., consid.risk fact.in pres.of GI   elev.bone turnover, discont.ther.& init. appropr.orthopaed.care in pts.  reacts., incr. sweat., back/skelet./bone/general./chest pain, myalg.,
   probl. eg. duodenit./dysphag./gastrit./ulc./symptomat. oesophag.dis.,   with stress fract., prior preventat.dentistry in pts with concom.jaw   arthralg., musc.cramps, osteonecros.of jaw predomin.in Ca pts., ren.
   alert to S&S of poss.oesophag. react., pts.to follow admin.instruct.  osteonecros.risk fact.& to avoid invas.dent. proced.while on treatm.,   toxic./impairm./fail., UTI, haematur., proteinur., flu-like sympt., as-
   carefully, consid. poss.causes of osteoporos.other than oestrog.defic./  dent.surg.poss. exacerbat. jaw osteonecros.while on ther.& no data   then., dehydrat., fatig., fev., rigors, weakn., periph./leg oed., malaise,
   ageing.& glucocorticoid use  avail.to suggest discont.ther.will reduc.risk theref.each pt.to be eval.  weight incr., hyper-/hypokalaem., hypomagnesaem., hypernatraem.,
   Drug interactions: Ca supplem./antacids & some oral meds.may   on benef./risk assessm.  hypocalcaem., hypophosphataem., hypotens.poss.lead.to circulat.
   interfere with absorpt.      Drug interactions: Addit.hypocalcaem.effs with aminoglycosides,   collapse esp.with underly.risk fact., hypertens.
                                system.expos.incr.to meds.prim. excret.by kidn.in ren.impairm.  Special precautions: Teratogen.in rats, ensure adeq. hydrat.prior to
   ZOBONE, Ranbaxy [P/S]                                      admin., fact.incr.ren.funct. deteriorat. potent.incl.dehydrat./pre-exist.
   Zoledronic acid              ZOLAPOR, Activo [P/S]         ren. impairm./ multipl. bisphosphon.treatm.cycl./other concom. ne-
   Indications: Tumour-induc.hypercalcaem., osteolyt. les.of multiple   Zoledronic acid  phrotox.meds & admin.over short. infus. time than recomm., avoid
   myeloma in conjunct. with std.antineoplast.ther., breast Ca with met-  Indications: Tumour-induc.hypercalcaem., progress. of skelet.condit.  overhydrat.in CF risk pts., bronchoconstrict.in aspir.-sens. asthmat.
   astat. bone les.in combinat.with appropr.anti-cancer ther., prostate   slow.in adults in combinat. with appropr.antineoplast.ther.in advanc.   assoc. with bisphosphonat., monit.ser.lev.of Ca/ phosph/ Mg & ser
   Ca with bone metastases where PSA lev. incr.despite hormon.ther.  Ca breast/prostate/lung & myeloma.  creatin.per.dur.ther.& supplem. if necess., regul.assessm.of pre-ex-
   (S4) POWD.FOR SOL.FOR INFUS, 42/34/0664  (S4) CONC.SOL.FOR INFUS, 45/34/0033  ist.anaem./ leukopen./ thrombocytopen., low.dos.recomm.in bone
   715952-001: 4 mg, 1x5 ml vial, R1 032,93  720613-001: 4 mg/5 ml, 1x 5 ml, R1 058,77  metast., caref.ren.funct.monit.init./dur./aft. ther.incl.elderly, dent.
   Dosage: Osteolyt.les.of multiple myeloma in conjunct.with   Dosage: Tumour-induc.hypercalcaem: Adults & elderly:   exam.bef.init.ther.in pts.with concom. risk fact., avoid invas.dent.
   std.antineoplast.ther., breast Ca with metastat. bone les.in   Recomm.dos.(Albumin-correct. ser. calcium &gt; 12,0 mg/dL or   proced. dur. ther., dent.surg.poss.exacerb.condit.if osteonecros. of
   combinat.with appropr.anti-cancer ther., prostate Ca with   3,0 mmol/L) is 4 mg giv.as IV infus.over at least 15 mins. Refer to   jaw devel.dur.ther., good oral hygiene/reg.dent. check-up advis.,
   bone metastases where PSA lev.incr. despite hormon.ther:   prod.lit.for dilut. & IV admin.  benef.-risk eval.in sev.ren.funct. impairm.
   Adults & elderly: 4 mg as 15 min. infus. every 3-4 wks.  Skelet.condits.in pts.with advanc. malign. involv. bone: 4 mg   Drug interactions: Addit.eff.with aminoglycos. low.ser.Ca lev.
   Tumour-induc.hypercalcaem: Adults & elderly: Recomm.dos.  giv.as IV infus.over at least 15 mins. repeat.every 3-4 wk. Refer to   for prolong.per., incr.hypocalcaem. risk with loop diurets., incr.ren.
   (Albumin-correct. Ser.Ca &gt; 12,0 mg/dL or 3,0 mmol/L) is 4 mg dil.in   prod.lit.for dilut. & IV infus.admin. Admin.oral 500 mg calcium sup-  dysfunct.risk with thalidomide, jaw osteonecros.risk with corticos-
   100 ml NaCl 0,9%/5% gluc.sol.as sngl.IV infus.over 15 mins. Maint.  plem.& 400 IU Vit.D dly.  ter. &/ chemother.
   pt.hydrat.prior to & follow.admin.  Skelet.relat.events in pts.with advanc. malign. involv.bone:   ZOMEDRON, Cipla Medpro [P/S]
   Re-treatm.of tumour-induc.hypercalcaem: Poss.if ser.Ca not   Based on ser.creatin.lev.& clear. determin. Recomm.dos: Baseline   Zoledronic acid
   return.to norm./does not remain norm.aft.init.treatm.in respond.  creatin. clear.(ml/min): &gt;60: 4,0 mg, 50–60: 3,5 mg, 40-49: 3,3 mg,   Indications: Tumour-induc.hypercalcaem., osteolyt. les.of multiple
   pts. Commenc. only 1 wk aft.init.treatm. Reconstit. 2x4 mg vials dil.  30-39: 3,0 mg. Meas.ser.creatin.bef.every dos. withhold.if ren.funct.  myeloma in conjunct. with std. antineoplast. ther., breast Ca with met-
   in 100 ml NaCl 0,9%/5% gluc. sol. Meas.ser.creatinine bef.every   deterior.resum.only when return.to within 10% of baseline values.   astat. bone les.in combinat.with appropr.anti-cancer ther., prostate
   dos. Median time to relapse is 30 days with 4 mg dos & 40 days   See prod. lit.for instruct.for prep.reduc.dos. Liq.conc. must be furth.  Ca with bone metastases where PSA lev. incr.despite hormon.ther.,
   with 8 mg dos.               dil.in 100 ml NaCl 0,9% or 5% gluc. sol.and admin.as sngl.IV infus.  slow. skelet. condit.progress. when used in conjunct. with appropr.
   Contraindications: Sev.imp.ren./liv.funct., pregn.& lactat., safety &   in a separ.line over no less than 15 min. Min.of 7 days bef. retreatm.  antineoplast.ther.in adults with advanc. lung Ca.
   effic.in paed.pts.not est., do not mix.with Ca contain.sols.  Contraindications: Sev.imp.ren.funct., pregn.& lactat.  (S4) POWD.FOR SOL.FOR INFUS, 43/34/0613
   Side effects: Thrombocytopen., anaem., leucopen., pancytopen.,   Side effects: Bld.dyscras., hypersens., angioed., psych./eye/card./  717192-001: 4 mg, 1 vial, R1 060,39
   CNS effs., paraesthes., taste disturbs., hypoaesthes., hyperaesthes.,   hepato-bil./ren./urin.disords., CNS effs., headache, tremor, dizzin.,   Dosage: Osteolyt.les.of multiple myeloma in conjunct.with
   trem., psych.disords., conjunctivit., blurr.vis., GI disturbs., stomat., dry   taste pervers., conjunctivit., blurr.vis., ocul.disturbs., vertigo, hypo-/  std.antineoplast.ther., breast Ca with metastat. bone les.in
   mouth, dyspn., cough, rash, prurit., incr.sweat., bone pain, myalg., ar-  hypertens., dyspn., pleur.effus., URTI, bronchosp., interstit.pneumonit.,   combinat.with appropr.anti-cancer ther., prostate Ca with
   thralg., musc.cramps, bradycard., ren./urin. disords.incl.ac.ren.fail.,   GI disords. incl.dysphag., mucosit., stomatit., thirst, skin reacts., mon-  bone metastases where PSA lev.incr. despite hormon.ther.,
   hypersens.reacts.incl. angioneurot. oed., fev., flu-like syndr., asthen.,   ilias., alopec., incr.sweat., back/ skelet./ bone/chest/orbit. pain, ar-  skelet.condits.in pts.with advanc.lung Ca involv.bone: Adults
   periph.oed., inj.site reacts., chest pain, weight incr., hypophospha-  thralg., myalg., musc. cramps, UTI, ren.toxic./fail., loc.reacts., flu-like   & elderly: 4 mg reconst.& furth. dilut. with 100 ml NaCl 0,9% / 5%
   taem., incr.bld.creatinine, hypocalcaem., hypomagnesaem., hyper-/  sympt., asthen., dehydrat., fatig., fev., oed., rigors, weakn., weight   gluc.sol. giv.as 15 min. IV infus. every 3-4 wks.
   hypokalaem., hypernatraem., ren.toxic.  incr., hypocalcaem., hypokalaem., hypomagnesaem., hyperkalaem.,   Tumour-induc.hypercalcaem: Adults & elderly: Recomm.dos.
   Special precautions: Teratogen.in rats., ensure adeq.hydrat.prior   hypophosphataem., hypernatraem.  (Albumin-correct. ser.Ca &gt;12,0 mg/dL or 3,0 mmol/L) is 4 mg recon-
   to admin., monit.ser.lev.of Ca/ phosph/Mg & ser creatinine aft.init.  Warnings: Bronchoconstrict.in aspir.-sens. asthmat. assoc.with bis-  stit. & furth. dil. with 100 ml NaCl 0,9%/5% gluc.sol.as sngl.15 min.
   ther.& supplem. if necess., fact.incr.ren.funct. deteriorat. potent.incl.  phosphonat., avoid overhydrat. in card.dis.risk pts.esp.elderly, ensure   IV infus. Maint.pt.hydrat.prior to & follow.admin.
   dehydrat./pre-exist.ren. impair. & nephrotox.meds., caref.monit.of ren.   adeq. hydrat.bef.init.ther.& theraft., monit.ser.lev. of Ca/ electrol./  Re-treatm.of tumour-induc.hypercalcaem: Poss.if ser.Ca not
   funct.dur.ther., benef.-risk eval.in concom. chemother. & corticoster.  phosph/Mg & K  per.dur.ther.& supplem. if necess., per.CBC monit.   return.to norm./does not remain norm. aft.init.treatm.in respond.
                                       +
   treatm., avoid overhydrat. in CF risk pts., bronchoconstrict.in acetyl-  esp.in pre-exist.anaem./leucopen./thrombocytopen., fact.incr. ren.   pts. Admin.at least 1 wk aft.init.treatm. Reconstit. 2x4 mg vials &
   salicyl. acid sens.asthmat.assoc.with bisphosphonates.  funct.deteriorat.potent.incl.dehydrat./pre-exist. ren.impairm./multipl.  dil. with 100 ml NaCl 0,9%/5% gluc.sol. Median time to relapse is
   Drug interactions: Loop diuret.may incr. hypocalcaem. risk, addit.  bisphosphon. treatm. cycl./other concom. nephrotox.meds./sngl.dos.   30 days with 4 mg dos.& 40 days with 8 mg dos.
   eff.with aminoglycos. with low.ser.Ca lev.  exceed. 4 mg & admin.over short.infus.time than recomm., ser.crea-  Contraindications: Sev.ren./liv.funct.impairm., safety & effic.in
                                tin.& ren.funct.determ.bef./dur.& period.aft.ther., ser.creatin.eval.bef.  pregn./lactat.& paed.pts.not est., do not mix.with Ca contain.sols.
   ZOCLASTA, (Austell) Camox    each dos.in case of repeat.ther., dent. exam.bef.init.ther.in pts. with   Side effects: Incr.ser.creatin.with chron.use, osteonecros.of jaw pre-
   Zoledronic acid              concom.risk fact., avoid dent.proced.dur. ther. as jaw osteonecros.  domin.in Ca pts.receiv. treatm. regim./assoc.with tooth extract.&/loc.
   Indications: Osteoporos.in postmenopaus.women to reduc.incid.  poss.exacerbat., good oral hygiene to be maint./reg.dent.check-ups   infect., thrombocytopen., anaem., leucopen., pancytopen., hypersens.
   of hip/vertebr.& non-vertebr.fract.& incr. bone min.density, reduct.of   advis., limit. data in sev.hepat.insuff., safety & effic.in paed. pts.not   reacts.incl.angioneurot. oed., psych.disords., CNS effs., headache, diz-
   new clinic.fract.in pts with rec.low trauma hip fract., osteoporos.in   est., teratogen.in rats, do not mix. with calcium contain.sols., jaw   zin., paraesthes., tremor, taste disturbs., conjunctivit., eye disords.,
   men, glucocortic.-induc.osteoporos., Paget’s dis.  osteonecros.main. in Ca pts.with concom.risk fact., hypotens.lead.  blurr.vis., hypertens., hypotens.poss. lead. to syncope/circulat.col-
   (S4) SOL.FOR INFUS., 49/34/1081. 5 mg/100 ml  to syncope/ circulat.collapse esp.in pts.with risk fact., elderly esp.  lapse esp.with underly. risk fact., bradycard., dyspn., cough, GI dis-
   723577-001: 1x100 ml, R3 156, 87  with ren.funct.impairm.  turbs., stomatit., dry mouth, incr.sweat., skin reacts., bone/ general./
   Dosage: Admin.paracet./ibuprof.shortly follow. ther. to reduc.post-  Interactions: Addit. eff.with aminoglycos. low. ser.Ca lev.for pro-  chest pain, myalg., arthralg., musc.cramps, ren./urin.disords.incl.ac.
   dos.sympts. Adeq.hydrat.prior to ther.esp.in elderly & diuret.ther. Ad-  long.per., pts.poss.at risk for jaw osteonecros.with chemother.&/  ren. fail., haematur., fev., flu-like syndr., asthen., periph. oed., inj.site
   min.IV via vented infus.line at const. infus.rate. over at least 15 mins.   corticoster., incr. hypocalcaem. risk with loop diurets., incr.ren. dys-  reacts., weight incr., hypophosphataem., hypocalcaem., hypomagne-
   Do not allow to come in contact with any Ca contain.sols.  funct. risk with thalidomide.  saem., hyper-/hypokalaem., hypernatraem., ren.toxic.
   Postmenopaus.osteoporos: Sngl.IV infus.of 5 mg admin.yearly  Special precautions: Ensure adeq.hydrat.prior to admin., avoid ove-
   Male osteoporos: Sngl.IV infus.of 5 mg admin. yearly  ZOMABON, (Eurolab) Actor [P/S]  rhydrat.in CF risk pts., monit.ser. lev. of Ca/phosph/Mg & ser.creatin.
   Glucocortic.-induc.osteoporos: Sngl.IV infus.of 5 mg admin.yearly  Zoledronic acid  aft.init.ther.& supplem. if necess., fact.incr.ren.funct.deteriorat. potent.
   Paget’s dis Only by experience.med.practit. Adeq. vit.D intake   Indications: Tumour-induc.hypercalcaem., progress. of skelet.condit.  incl.dehydrat./pre-exist.ren.impairm.& nephrotox. meds./multip.bispho-
   recomm.dur.treatm.& furth.Ca supplementat. of 500 mg elem.Ca   slow.in adults in combinat. with appropr.antineoplast.ther.in advanc.   sphonate treatm. cycles & admin.over short.infus.time than recomm.,
   2xdly x10 days follow. admin. Recomm.dos: One IV infus.of 5 mg   Ca breast/prostate/lung & myeloma.  caref.ren.funct.monit.dur.ther.& consid. potent. benef./risk of cont.ther.
   in 100 ml aqueous sol.via vented infus.line at const. infus.rate. Re-  (S4) CONC.SOL.FOR INFUS, 45/34/0435  in pts.with ren. funct. deteriorat., dent.exam.with appropr. prevent. den-
   treatm: Specif.data not avail. Extend. remiss.gen.observ.in respond.  719858-001: 4 mg/5 ml, 1x5 ml vial, R1 040,42  tistry advis.in pts.with risk fact., those at risk to avoid invas.proced.dur.
                                                              ther.if poss., dent. surg. poss.exacerb.condit.if osteonecros.of jaw de-
   pts.aft.a sngl. treatm. Re-treatm.may be consid.bas.on incr. ser. alkal.  Dosage: Adults & elderly: Tumour-induc. hypercalcaem:
   phosphat/fail.to achieve normalisat.of ser. alkal.phosphat./in pts.with   Recomm.dos.(Albumin-correct. serum Ca &gt; 12,0 mg/dL or 3,0 mmol/L)   vel. while on bisphosphonate ther., bronchoconstrict. in acetylsalicyl.
                                                              acid-sens. asthmat. assoc.with bisphosphonates., benef.-risk eval. in
   sympts.dictat.by medic. pract.12 mnths aft.init.dos.  is 4 mg giv. as IV infus.last.at least 15 mins. Maint.pt. hydrat. prior to
   Contraindications: Any bisphosphon.hypersens., hypocalcaem.,   & follow.admin. Refer to prod.lit.for conc. dilut. & IV admin.  pts. with hypercalcaem.of malign.who also have sev.ren. funct.impairm.
                                                              Drug interactions: Poss.addit.eff.with aminoglycosid., incr.kidn.
   pregn.& lactat., sev.ren.fuct. impairm., treatm.with another bispho-  Skelet.condits.in pts.with advanc.malign. involv. bone: Recon-  dysfunct.risk with concom. thalidomide in multip.myeloma pts.
   sphon., childr. & adolesc.bel.18 yrs.  stit.4 mg in 5 ml H 2O then furth. dil.in 100 ml NaCl 0,9%/5% gluc sol.
   Side effects: Hypersens., angioed., anaphylact. react./shock, influen-  as IV infus. over at least 15 mins.& repeat.every 3-4 wks. Admin.oral   ZOMETA, Novartis [P/S]
   za., nasopharyngit., anaem., anorex., decr.appet., insomn., headache,   500 mg Ca supplem.& 400 IU Vit. D dly.  Zoledronic acid
   dizzin., lethargy, paraesthes., somnol., trem., syncope, conjuctivit., eye   Skelet.relat.events in pts.with advanc. malign. involv.bone:   Indications: Tumour-induc.hypercalcaem., progress. of skelet.condit.
   pain, uveitis., episclerit., iritis, vertigo, atrial fibrillat., hyper-/hypotens.,   Based on ser.creatin.lev.& clear.determin. Recomm.dos: Baseline cre-  slow.in adults in combinat. with appropr.antineoplast.ther.in advanc.
   flush., cough, dyspn., GI disords., gastroesophag.reflux, oesophagit.,   atinine clear. (ml/min): &gt;60: 4,0 mg, 50–60: 3,5 mg, 40-49: 3,3 mg, 30-  Ca breast/prostate/lung & myeloma.
   rash, hyperhidros., prurit., erythema, myalg., arthralg., bone/back/ex-  39: 3,0 mg. Meas.ser.creatinine bef. every dos.withhold.if ren.funct.  (S4) CONC.SOL.FOR INFUS, 38/34/0086
   tremity/shoulder /musculoskelet.& neck pain, musculoskelet.-/joint   deterior.resum.only when return to within 10% of baseline values.   708533-001: 4 mg, sngl.vial, R1 051,42</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page112.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page108.html">108</a>&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>&nbsp;&nbsp;&nbsp;<a href="page112.html">112</a>&nbsp;&nbsp;&nbsp;<a href="page113.html">113</a>&nbsp;&nbsp;&nbsp;<a href="page114.html">114</a>&nbsp;&nbsp;&nbsp;<a href="page115.html">115</a>&nbsp;&nbsp;&nbsp;<a href="page116.html">116</a>&nbsp;&nbsp;&nbsp;<a href="page117.html">117</a>&nbsp;&nbsp;&nbsp;<a href="page118.html">118</a>
             </td>
             <td width="35%"><a href="page114.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page114.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
